drugset / Trial / NCT02900664
A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study was to combine the PDR001 checkpoint inhibitor with each of four agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.
Timeline
- Start
- 2016-08-23
- Primary completion
- 2021-03-17
- Completion
- 2021-03-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CJM112 | Monoclonal antibody | 25 mg | Intravenous |
| Subject | CJM112 | Monoclonal antibody | 75 mg | Intravenous |
| Subject | CJM112 | Monoclonal antibody | 225 mg | Intravenous |
| Subject | CJM112 | Monoclonal antibody | 450 mg | Intravenous |
| Subject | CJM112 | Monoclonal antibody | 900 mg | Intravenous |
| Subject | CJM112 | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Canakinumab | Monoclonal antibody | 100 mg | — |
| Subject | Canakinumab | Monoclonal antibody | 300 mg | — |
| Subject | Nazartinib | Small molecule | 25 mg | — |
| Subject | Nazartinib | Small molecule | 50 mg | — |
| Subject | Spartalizumab | Monoclonal antibody | — | Intravenous |
| Subject | Trametinib | Small molecule | 0.5 mg | — |
| Subject | Trametinib | Small molecule | 1 mg | — |
| Subject | Trametinib | Small molecule | 1.5 mg | — |